REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Regulatory News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.80
High: 0.80
Low: 0.80
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-year Report

30 Sep 2016 12:19

RNS Number : 3626L
Onzima Ventures PLC
30 September 2016
 

ONZIMA VENTURES PLC

("Onzima" or the "Company")

 

Unaudited interim results for the 6 months ended 30 June 2016

Onzima Ventures plc is pleased to announce its unaudited interim results for the six months ended 30 June 2016.

 

Highlights

· Numerous investments made during the period

· A number of successful partial and full disposals of positions

· Warrant / option positions building

· Asset Trading and Business Development divisions created

· 49% stake in N4 Pharma Limited held in Business Development division

· Share price increase of 205% in period under review

· Cash at period end of £369,000

 

Chief Executive Officer's review

The Company made a loss after tax of £29,000 for the six months ended 30 June 2016 compared to a loss of £70,000 for the same period in 2015. We are pleased with the development of our investment portfolio where, with the exception of our 49% stake in N4 Pharma Limited, the holdings comprise AIM-traded investments and cash.

Gavin Burnell, Chief Executive Officer of Onzima, stated:

"We have been successful during the first half of 2016 to not only make investments at what the Board consider to be attractive terms but also to realise gains where appropriate for the purpose of making new investments to minimise dilution for shareholders, cover our overheads and to demonstrate the viability of our business model as we have grown by virtue of our level of activity and performance.

Our first investment of 2016 was the acquisition of a 49% equity stake in N4 Pharma Limited together with the provision of a loan facility to N4 Pharma, a drug reformulation company. During the period we have experienced very good returns on a number of our investments including for example Ferrum Crescent Ltd, Glenwick plc and Jubilee Platinum plc. Since the period end we have seen further share price appreciation from the majority of our holdings including Alecto Minerals plc, Ferrum Crescent Ltd, Hummingbird Resources plc, Jubilee Platinum plc, Kolar Gold Ltd and Prospex Oil & Gas plc. In addition we have recently invested £50,000 in to a fundraising by Savannah Resources plc and £60,000 in to Alecto Minerals plc today, both of which are trading at a healthy premium to the placing prices.

At the period end we held cash of £369,000, tradable investments valued at market at £175,500 plus warrants and options, a 49% stake in N4 Pharma Limited and a loan to N4 Pharma of £125,000.

Onzima now holds positions comprised of equity and/or warrant/options in the following companies:

Trading Division

 

 

Alecto Minerals plc

Bezant Resoures plc

Bushveld Minerals Limited

Ferrum Crescent Limited

Hummingbird Resources plc

Jubilee Platinum plc

Kolar Gold Ltd

MX Oil plc

Prospex Oil & Gas plc

Regency Mines plc

Savannah Resources plc

Valirx plc

 

Business Development Division

 

N4 Pharma Limited (49% equity stake plus loan)

 

 

The key unaudited performance indicators are set out below.

 

COMPANY STATISTICS

30 June 2016

31 December 2015

Change %

Closing share price

1.68

0.55p

+205%

Market capitalisation

£3,056,870

£762,475

+301%

Since becoming an investing company and prior to 31 December 2015, the Company had only made one investment - in Glenwick plc, where it invested £50,000 and realised £75,500 after costs in January 2016.

During this interim period of 2016 the Company has been very active, negotiating and completing on the acquisition of a 49% equity holding in N4 Pharma Limited and participating in numerous secondary fundraisings deploying in total £684,000 of cash resources. In addition, the Board is confident of completing on its second investment by its Business Development division shortly.

 

 

 

G Burnell

Chief Executive Officer

30 September 2016

 

Consolidated Statement of Comprehensive Income

Six Months ended 30 June 2016

 

 

Unaudited

Half year

Unaudited Half Year

Audited

Full Year

2016

2015

2015

£000's

£000's

£000's

Continuing Operations

Revenue

486

615

-

Cost of Sales

390

203

-

Gross Profit

96

412

-

Selling and administration expenses

125

479

160

Other Operating Income

-

-

-

Operating (Loss)

(29)

(67)

(160)

 

Exceptional Items

 

 

 

 

 

 

Finance Cost

-

(3)

(4)

 (Loss) before taxation

(29)

(70)

(164)

Taxation recovery

-

-

13

Loss for the year from discontinued operations

-

-

(902)

Exchange difference on translating foreign operations

-

-

53

Total comprehensive (Loss) for the period attributable to equity holders of the Company

(29)

(70)

(1,000)

Basic and diluted (loss) per share -pence

(0.002)

(0.025)

(0.86)

 

 

 

Consolidated Statement of financial position

 

30/06/2016

Unaudited

Half year

30/06/2015

Unaudited Half Year

31/12/2015

Audited

Full Year

2016

2015

2015

£000's

£000's

£000's

ASSETS

Non-Current assets

Property, plant, equipment

-

613

-

Investments

189

-

50

Total non-current assets

189

613

50

Current assets

Inventories

194

335

-

Trade and other receivables

48

483

21

Cash and other equivalents

369

94

587

Total current assets

611

912

608

Total assets

800

1,525

658

LIABILITIES

 

Non-Current liabilities

Deferred tax

-

-

-

Total noncurrent liabilities

-

-

-

Current Liabilities

Trade and other payables

-

254

-

Current tax liabilities

-

65

-

Accruals and deferred income

33

234

17

Total current liabilities

33

553

17

Total liabilities

33

553

17

Net assets

783

972

641

EQUITY

Capital and reserves attributable to equity holders of the Company

Called up share capital

8,564

8,299

8,409

Share premium account

6,503

5,843

6,503

Other reserves

31

202

31

Retained earnings

(14,331)

(13,319)

(14,302)

Translations of foreign operations

-

(53)

-

Total equity

767

972

641

 

Consolidated statement of cash flows

Unaudited

Half year

Unaudited Half Year

Audited

Full Year

2016

2015

2015

£000's

£000's

£000's

Cash Flows from operating activities

 (Loss) for the financial period`

(29)

(70)

(1,053)

Taxation expense

-

-

(13)

Interest receivable

-

-

4

Interest payable

-

3

-

Exchange variance

-

-

53

Depreciation charges

-

13

230

Movement in reserves

-

-

(171)

Operating profit before changes in working capital

(29)

(54)

(950)

Decrease/(Increase) in inventories

(194)

12

347

Decrease/(Increase) in trade and other receivables

(27)

56

518

(Decrease)/increase in trade payables and other current liabilities

 

16

(254)

(790)

Cash (used in)/generated from operations

(234)

(240)

(875)

Taxation

-

-

13

Net cash (used in)/generated by operating activities

(234)

(240)

(862)

Cash flow from investing activities

Purchase of property, plant and equipment

-

(10)

386

Development expenditure

-

-

-

Movement in investments

(139)

-

(50)

Net proceeds of ordinary share issue

155

-

770

Net cash used in investing activities

16

(250)

1,106

Cash flows from financing activities

Interest (received)/payable

-

(3)

(4)

Net cash(used in)/generated by financing activities

-

(3)

(4)

Net increase/(decrease) in cash and cash equivalents

(218)

(253)

240

Cash and cash equivalents at beginning of the period

587

347

347

Cash and cash equivalents at end of the period

369

94

587

 

 

 

 

Consolidated statement of changes in equity

 

(i) Six months ended 30 June 2016 - unaudited

 

Called up share capital

Share Premium

Other

reserves

Retained earnings

Translation of foreign operations

Total Equity

At 1 January 2016

8,409

6,503

31

(14,302)

-

641

Loss for the period

-

-

-

(29)

-

(29)

Share issue

155

-

-

-

-

155

At 30 June 2016

8,564

6,503

31

(14,331)

-

767

 

 

 

(ii) Six months ended 30 June 2015 - unaudited

 

Called up share capital

Share Premium

Other

reserves

Retained earnings

Translation of foreign operations

Total Equity

At 1 January 2015

8,299

5,843

202

(13,249)

(53)

1,042

Loss for the period

-

-

-

(70)

-

(70)

At 30 June 2015

8,299

5,843

202

(13,319)

(53)

972

 

 

(iii) Year ended 31 December 2015 - Audited

 

Called up share capital

Share Premium

Other

reserves

Retained earnings

Translation of foreign operations

Total Equity

At 1 January 2015

8,299

5,843

202

(13,249)

(53)

1,042

Total comprehensive income for the year

-

-

-

(1,053)

53

(1,000)

Share issue

110

660

-

-

-

770

Movement in reserves

-

-

(202)

-

-

(202)

Share option reserve

-

-

31

-

-

31

At 31 December 2015

8,409

6,503

31

(14,302)

-

641

 

 

 

 

1. Segmental reporting

 

The Group operated in the United Kingdom, Italy and Spain until subsidiaries were sold on 14 October 2015.

 

Prior to disposal, the Group was organised into two principal business segments:

 

• IT and related services (comprising legal and publishing application software)

 

• Green technology (comprising electric bicycles, energy saving lamps, educational electronic kits and development of solar power parks)

 

The company now operates as an investment holding company and in the United Kingdom only.

 

The segmental results for the half year ended 30 June 2016 are as follows:

 

Unaudited

Half year

Unaudited Half Year

Audited

Full Year

2016

2015

2015

£000's

£000's

£000's

Revenue

United Kingdom

486

615

-

Total

486

615

-

 

Revenue

IT Services Division

-

353

-

Green Technology Division

-

262

-

Share Dealing

486

-

-

Total

486

615

-

Operating profit before exceptional items

IT Services Division

-

122

-

Green Technology Division

-

(91)

-

Unallocated

-

(98)

(160)

Share Dealing

(29)

-

-

(Loss) before Finance Charges

(29)

(67)

(160)

Finance Income/(payable)

-

(3)

(4)

Operating (loss)

(29)

(70)

(164)

Taxation Recovered

-

-

13

Exchange difference on translating foreign operations

-

-

53

Loss for the year from discontinued operations

-

-

(902)

Loss before taxation

(29)

(70)

(1,000)

 

 

 

 

Unaudited

Half year

Unaudited Half Year

Audited

Full Year

2016

2015

2015

£000's

£000's

£000's

Depreciation

IT Services (UK)

-

1

-

Green technology division

-

-

-

Unallocated

-

12

-

Group Total

-

13

-

Segment Assets

IT Services (UK)

-

746

-

Green technology division

-

779

-

Share dealing

800

-

658

Group

800

1,525

658

Segmental liabilities

IT Services (UK)

-

(410)

-

Green technology division

-

(143)

-

Share dealing

(33)

-

(17)

Group

(33)

(553)

(17)

Net assets

IT Services (UK)

-

336

-

Green technology division

-

636

-

Share dealing

767

-

641

Group

767

972

641

Capital Expenditure

IT Services (UK)

-

10

-

Green technology division

-

-

-

Green Technology Division (disposals)

-

-

-

 

Group

-

10

-

2 Basis of preparation

The consolidated interim financial statements have been prepared in accordance with the AIM Rules for Companies and prepared on a basis consistent with International Financial Reporting Standards ("IFRS") as adopted by the EU and the accounting policies set out in the Group's financial statements for the year ended 31 December 2015.

 

The interim financial statements do not constitute statutory accounts within the meaning of section 435 of the Companies Act 2006.

 

The consolidated interim financial statements are unaudited and include all adjustments which management considers necessary for a fair presentation of the Group's financial position, operating results and cash flows for the 6 month periods ended 30 June 2016 and 30 June 2015.

 

The Group has chosen not to adopt IAS 34 'Interim Financial Statements' in preparing these interim financial statements and therefore the interim financial information is not in full compliance with IFRS disclosure.

 

The preparation of interim financial statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. Actual results may differ from these estimates.

 

These interim financial statements have been prepared under the historical cost convention.

 

3 Taxation

Due to expected availability of brought forward losses, no provision has been made for application of tax for the period under review.

 

4 Dividends

The Company has not proposed or declared an interim dividend.

 

5 Earnings per share

Basic earnings per share has been calculated based on the profit / (loss) on ordinary activities after taxation and the weighted average number of shares in issue for the period of 142,701,099 (June 2015: 279,176,538 and December 2015: 249,527,403). There are no options having a dilutive impact on earnings per share.

 

6 Other information

This interim statement was approved by the Board on 30 September 2016 and has not been reviewed by the Company's accountants Hills Jarrett LLP. The comparatives for the full year ended 31 December 2015 are not the Company's full statutory accounts for that year. A copy of the statutory accounts for that year, which were prepared under IFRS, has been delivered to the Registrar of Companies. The auditors' report on those accounts was unqualified, did not include references to any matters to which the auditors drew attention by way of emphasis without qualifying their report and did not contain a statement under section 498 (2) or (3) of the Companies Act 2006.

No adjustments have been made for any changes in estimates made at the time of approval of the 2016 accounts.

 

A copy of this interim statement will be available shortly at the Company's registered office at Onzima Ventures plc, 190 High Street, Tonbridge, Kent, TN9 1BE and on the Company's website www.onzimaventures.com

 

The Company is an investing Company and pursuant to the AIM Rules it is required to have fulfilled its investing policy to the satisfaction of the London Stock Exchange by 14 October 2016, otherwise the Company's shares will be suspended from trading on Aim for a period of up to 6 months, and following that 6 month period the Company's admission to trading on AIM would be suspended.

 

Ends

 

For further information please contact:

Onzima Ventures PLC Tel: +44 (0) 1732 366 561Gavin Burnell, Luke Cairns

Nominated AdviserCairn Financial Advisers LLP Tel: +44 (0) 20 7148 7900 Sandy Jamieson, Liam Murray

 

BrokerPeterhouse Corporate Finance Limited Tel: +44 (0) 20 7469 0930 Guy Miller, Lucy Williams

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR FBLFXQKFFBBD
Date   Source Headline
29th Apr 202410:59 amRNSPosting of Annual Report & Notice of AGM
26th Apr 20247:00 amRNSN4 Pharma Webinar on SRI Collaboration
25th Apr 20247:38 amRNSCollaboration Agreement with SRI International Inc
23rd Apr 20247:00 amRNSFinal Results
18th Apr 20247:00 amRNSOral Delivery Update
4th Mar 20243:13 pmRNSHolding(s) in Company
29th Feb 20247:00 amRNSHolding(s) in Company
15th Feb 20247:00 amRNSin-vitro siRNA update
19th Jan 20247:00 amRNSPatent Grant
18th Jan 202410:15 amRNSHolding(s) in Company
16th Jan 20247:00 amRNSNanogenics Update
8th Jan 20244:24 pmRNSHolding(s) in Company
8th Jan 20247:00 amRNSAAV Viral Vector Update
18th Dec 20237:00 amRNSOral Delivery Update
7th Dec 202311:28 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSNuvec® R&D and Strategy Update
30th Nov 20239:00 amRNSN4 Pharma Launches New Interactive Investor Hub
31st Oct 20237:00 amRNSTotal Voting Rights
9th Oct 20237:00 amRNSInvestor Presentation via Investor Meet Company
3rd Oct 20238:15 amRNSHolding(s) in Company
2nd Oct 20237:00 amRNSInvestor Presentation
28th Sep 20237:00 amRNSAcquisition of Controlling Interest in Nanogenics
12th Sep 20237:00 amRNSInterim Results
25th Jul 20237:00 amRNSPatent Grant and Board Change
27th Jun 20237:00 amRNSGrant Award for Professor Chengzhong Yu
25th Apr 20237:00 amRNSsiRNA update
18th Apr 20237:00 amRNSsiRNA update
3rd Apr 20232:11 pmRNSResult of AGM
9th Mar 20237:00 amRNSPosting of Annual Report & Notice of AGM
9th Mar 20237:00 amRNSFinal Results
14th Feb 20234:40 pmRNSSecond Price Monitoring Extn
14th Feb 20234:35 pmRNSPrice Monitoring Extension
17th Jan 20232:05 pmRNSSecond Price Monitoring Extn
17th Jan 20232:00 pmRNSPrice Monitoring Extension
17th Jan 202311:05 amRNSSecond Price Monitoring Extn
17th Jan 202311:00 amRNSPrice Monitoring Extension
17th Jan 20239:05 amRNSSecond Price Monitoring Extn
17th Jan 20239:00 amRNSPrice Monitoring Extension
17th Jan 20237:00 amRNSOral application update
30th Nov 20225:28 pmRNSHolding(s) in Company
30th Nov 20227:00 amRNSTotal Voting Rights
25th Nov 20222:49 pmRNSHolding(s) in Company
22nd Nov 202210:50 amRNSResult of Broker Offer and Total Voting Rights
18th Nov 20227:01 amRNSBroker Offer to raise a maximum of £1 million
18th Nov 20227:00 amRNSPlacing to raise £1million and Broker Offer
1st Nov 20227:00 amRNSPatent filing update
4th Oct 20227:00 amRNSDouble siRNA Testing Update
29th Sep 20227:00 amRNSInterim Results
14th Sep 20227:00 amRNSOperational Update
15th Jul 20227:00 amRNSWork Programme Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.